Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02843126 | Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02844335 | Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03346161 | Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach | completed | Phase 1 | 120 | Washington University School of MedicineOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02307240 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | completed | Phase 1 | 43 | Curis, Inc.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01282580 | Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01375699 | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | completed | Phase 1 | 26 | Virginia Commonwealth UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02045368 | Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | completed | Phase 1 | 92 | IGF Oncology, LLCINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01390064 | Vaccination of High Risk Breast Cancer Patients | completed | Phase 1 | 6 | University of ArkansasOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00820170 | Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 | completed | Phase 1 / Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02683083 | Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients(CAM-VHH1) | completed | Phase 1 | 9 | PrecirixINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03810625 | Food Effect Study of D-0502 Tablet in Healthy Volunteers | completed | Phase 1 | 14 | InventisBio Co., LtdINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02619162 | Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics | completed | Phase 1 | 25 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | completed | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT01434303 | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | May 20, 2019 | clinicaltrials |
| NCT01597193 | Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | completed | Phase 1 | 101 | PfizerINDUSTRY | 1 | May 8, 2019 | clinicaltrials |
| NCT02833155 | Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 19 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT00912275 | Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 46 | National Taiwan University HospitalOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03109249 | Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 142 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT02145559 | A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02073916 | T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer(STELA) | completed | Phase 1 | 24 | Jenny C. Chang, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 85 | AbbVieINDUSTRY | 3 | Apr 5, 2019 | clinicaltrials |
| NCT03013881 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers | completed | Phase 1 | 18 | United BioPharmaINDUSTRY | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02723877 | PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) | completed | Phase 1 / Phase 2 | 41 | PIQUR Therapeutics AGINDUSTRY | 2 | Mar 22, 2019 | clinicaltrials |
| NCT01862900 | Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions(OX40 Breast) | completed | Phase 1 | 14 | Providence Health & ServicesOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01326481 | Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer(TRC105) | completed | Phase 1 / Phase 2 | 19 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Mar 18, 2019 | clinicaltrials |
| NCT00485277 | A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer | completed | Phase 1 | 9 | Bavarian NordicINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01152398 | A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy | completed | Phase 1 | 15 | Bavarian NordicINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00003002 | HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer | completed | Phase 1 | 60 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02580448 | CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)(CLARITY-01) | completed | Phase 1 / Phase 2 | 175 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02418624 | Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer(REVIVAL) | completed | Phase 1 | 25 | The Netherlands Cancer InstituteOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02655952 | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients | completed | Phase 1 | 17 | WntResearch ABINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT00001507 | Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer | completed | Phase 1 | 107 | National Cancer Institute (NCI)NIH | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02883985 | Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers | completed | Phase 1 / Phase 2 | 100 | NYU Langone HealthOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT00425672 | ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment | completed | Phase 1 / Phase 2 | 15 | University of WashingtonOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT03153163 | Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer | completed | Phase 1 | 11 | Hoffmann-La RocheINDUSTRY | 1 | Nov 23, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00005807 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer(BMS-247550) | completed | Phase 1 | 40 | Albert Einstein College of MedicineOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01632332 | Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer | completed | Phase 1 | 22 | Mayo ClinicOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 99 | Puma Biotechnology, Inc.INDUSTRY | 6 | Sep 26, 2018 | clinicaltrials |
| NCT00146172 | Study Evaluating HKI-272 in Tumors | completed | Phase 1 | 73 | Puma Biotechnology, Inc.INDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Sep 12, 2019source: clinicaltrials